• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DONEPEZIL Drug Record

  • Summary
  • Interactions
  • Claims
  • DONEPEZIL chembl:CHEMBL502 Approved

    Alternate Names:

    E-2020
    ARICEPT
    DONEPEZIL
    ARICEPT®
    DONEPEZILO
    DONEPEZILUM
    DOMEPEZIL
    pubchem.compound:3152
    chembl:CHEMBL502
    chemidplus:120014-06-4
    rxcui:135447
    drugbank:00843

    Drug Info:

    Year of Approval 1996
    Drug Class nootropic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of alzheimer's disease
    (4 More Sources)

    Publications:

    Kryger et al., 1999, Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Structure
    Davis, 1999, Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington., Geriatrics
    Shepherd et al., Donepezil overdose: a tenfold dosing error., Ann Pharmacother
    Repantis et al., 2010, Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review., Pharmacol. Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kosasa et al., 1999, Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats., Eur. J. Pharmacol.
    Jann, 2000, Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease., Pharmacotherapy
    Ki et al., 2010, Donepezil, a potent acetylcholinesterase inhibitor, induces caspase-dependent apoptosis in human promyelocytic leukemia HL-60 cells., Biol. Pharm. Bull.
    Sugimoto, 2001, Donepezil hydrochloride: a treatment drug for Alzheimer's disease., Chem Rec
    Huang L et al., 2014, Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease., Eur J Med Chem
    Braga IL et al., 2015, Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease., Am J Alzheimers Dis Other Demen
    Coin A et al., 2016, Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease., Eur J Clin Pharmacol
    Noetzli M et al., 2014, Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance., Br J Clin Pharmacol
    Yoon H et al., 2015, Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease., Pharmacopsychiatry
    Bullock et al., 2005, Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period., Curr Med Res Opin
    Heydorn, 1997, Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease., Expert Opin Investig Drugs
    Sokolow S et al., 2017, Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment., J Alzheimers Dis
    De Beaumont L et al., 2016, Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects., J Alzheimers Dis
    Scacchi R et al., 2009, Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine., Am J Med Genet B Neuropsychiatr Genet
    Blesa R et al., 2006, Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease., Pharmacogenet Genomics
    Liston DR et al., 2004, Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease., Eur J Pharmacol
    Seltzer B, 2005, Donepezil: a review., Expert Opin Drug Metab Toxicol
    Nordberg A et al., 2013, A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease., Prim Care Companion CNS Disord
    Ogura H et al., 2000, Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro., Methods Find Exp Clin Pharmacol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Leyhe et al., 2008, Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease., Eur Arch Psychiatry Clin Neurosci
  • DONEPEZIL   BCHE

    Interaction Score: 6.23

    Interaction Types & Directionality:
    inducer (activating)

    Interaction Info:

    PMIDs:
    16083542 15989517 27911294 27567841 18780301 17047484 14751402 16863459 23930233 11256231


    Sources:
    NCI PharmGKB

  • DONEPEZIL   ACHE

    Interaction Score: 3.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name donepezil hydrochloride, E2020,Aricept
    Novel drug target Established target

    PMIDs:
    10368299 10024872 10466911 20193764 11752352 10513568 10641971 20522977 11893059 25282266


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • DONEPEZIL   CHAT

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25730470


    Sources:
    PharmGKB

  • DONEPEZIL   CHRNA7

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24951635


    Sources:
    PharmGKB

  • DONEPEZIL   BDNF

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17990049


    Sources:
    NCI

  • DONEPEZIL   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • DONEPEZIL   CYP2D6

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26952092 24433464


    Sources:
    PharmGKB FDA

  • TEND: DONEPEZIL

    • Version: 01-August-2011

    Alternate Names:
    DONEPEZIL Primary Drug Name

    Drug Info:
    Drug Class nootropic agents
    Year of Approval 1996

    Publications:

  • TdgClinicalTrial: DONEPEZIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of alzheimer's disease
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: DONEPEZIL

    • Version: 14-September-2017

    Alternate Names:
    C2603 NCI drug code

    Drug Info:

    Publications:
    Heydorn, 1997, Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease., Expert Opin Investig Drugs
    Bullock et al., 2005, Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period., Curr Med Res Opin
    Leyhe et al., 2008, Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease., Eur Arch Psychiatry Clin Neurosci

  • DTC: DONEPEZIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL502 ChEMBL Drug ID

    Drug Info:

    Publications:
    Huang L et al., 2014, Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease., Eur J Med Chem

  • PharmGKB: donepezil

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Noetzli M et al., 2014, Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance., Br J Clin Pharmacol
    Coin A et al., 2016, Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease., Eur J Clin Pharmacol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

  • TTD: Donepezil

    • Version: 2020.06.01

    Alternate Names:
    D0NS6H TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL502

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Donepezil

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21